Aridis Pharmaceuticals, Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aridis Pharmaceuticals, Inc
The company said it would discontinue the Phase III trial of the MRSA drug for futility, leaving it with no major catalysts and an uncertain cash position.
Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Aridis is effectively pulling the plug on AR-105 after the mAb failed in a Phase II ventilator-associated pneumonia trial. It will now focus on its remaining pipeline, led by Phase III asset AR-301.
- Large Molecule
- Other Names / Subsidiaries
- Shenzhen Arimab Biopharmaceuticals Co., Ltd.